These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19237050

  • 21. Value of FDG PET in the management of NSCLC.
    Ukena D, Hellwig D.
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [Abstract] [Full Text] [Related]

  • 22. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
    Deuschl C, Nensa F, Grueneisen J, Poeppel TD, Sawicki LM, Heusch P, Gramsch C, Mönninghoff C, Quick HH, Forsting M, Umutlu L, Schlamann M.
    Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
    [Abstract] [Full Text] [Related]

  • 23. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M, Erelel M, Ece T, Mudun A.
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [Abstract] [Full Text] [Related]

  • 24. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA, McAdams HP, Herndon JE, Patz EF.
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [Abstract] [Full Text] [Related]

  • 25. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y, Dai HH.
    Chin Med J (Engl); 2007 Jan 20; 120(2):125-31. PubMed ID: 17335654
    [Abstract] [Full Text] [Related]

  • 26. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer.
    Takenaka T, Yano T, Ito K, Morodomi Y, Miura N, Kawano D, Shoji F, Abe K, Honda H, Maehara Y.
    J Surg Oncol; 2009 Dec 15; 100(8):688-92. PubMed ID: 19731260
    [Abstract] [Full Text] [Related]

  • 27. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
    Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N.
    Lung Cancer; 2011 Feb 15; 71(2):144-50. PubMed ID: 20646779
    [Abstract] [Full Text] [Related]

  • 28. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
    Li M, Wu N, Liang Y, Zheng R, Liu Y, Zhang WJ, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Apr 15; 31(4):288-92. PubMed ID: 19615286
    [Abstract] [Full Text] [Related]

  • 29. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y, He S, Dong J.
    Zhonghua Yi Xue Za Zhi; 2001 Oct 15; 81(19):1180-3. PubMed ID: 11769705
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M, Hara M, Sakurai K, Ozawa Y, Mizuno A, Tamaki T, Nishio M, Shibamoto Y.
    Acta Radiol; 2009 Jul 15; 50(6):638-44. PubMed ID: 19492198
    [Abstract] [Full Text] [Related]

  • 31. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
    Gauger J, Patz EF, Coleman RE, Herndon JE.
    J Thorac Oncol; 2007 Jun 15; 2(6):499-505. PubMed ID: 17545844
    [Abstract] [Full Text] [Related]

  • 32. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
    Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, Ruffini L, Bartolotti M, Bortesi B, Fumarola C, Caffarra C, Cavazzoni A, Alfieri RR, Petronini PG, Bordonaro R, Bruzzi P, Ardizzoni A, Soto Parra HJ.
    Cancer Chemother Pharmacol; 2014 Feb 15; 73(2):299-307. PubMed ID: 24258456
    [Abstract] [Full Text] [Related]

  • 33. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW, Yu JM, Xing LG.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct 15; 26(10):626-9. PubMed ID: 15634527
    [Abstract] [Full Text] [Related]

  • 34. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R.
    J Thorac Oncol; 2008 Feb 15; 3(2):135-9. PubMed ID: 18303433
    [Abstract] [Full Text] [Related]

  • 35. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan 15; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 36. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E, Wood DE.
    J Thorac Oncol; 2008 Sep 15; 3(9):971-8. PubMed ID: 18758298
    [Abstract] [Full Text] [Related]

  • 37. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA, Dietlein M, Hellwig D, Kirsch CM, Schicha H, Schwaiger M.
    Nuklearmedizin; 2003 Aug 15; 42(4):135-44. PubMed ID: 12937692
    [Abstract] [Full Text] [Related]

  • 38. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schäfers HJ.
    J Thorac Cardiovasc Surg; 2004 Dec 15; 128(6):892-9. PubMed ID: 15573074
    [Abstract] [Full Text] [Related]

  • 39. Prognostic value of 18-FDG uptake in early stage NSCLC.
    Chen JC, Huang TW, Cheng YL, Chang H, Tzao C, Huang WS, Lee SC.
    Thorac Cardiovasc Surg; 2009 Oct 15; 57(7):413-6. PubMed ID: 19795329
    [Abstract] [Full Text] [Related]

  • 40. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
    Kim SJ, Hwang SH, Kim IJ, Lee MK, Lee CH, Lee SY, Lee EY.
    J Exp Clin Cancer Res; 2010 Jun 12; 29(1):69. PubMed ID: 20540786
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.